Form 4: Opus Genetics CSO Sells Shares for Tax Obligations

Opus Genetics' Chief Scientific & Development Officer, Ashwath Jayagopal, sold 3,719 shares of common stock to cover tax withholding obligations.

Summary

• Ashwath Jayagopal, Chief Scientific & Development Officer of Opus Genetics, Inc. (IRD), reported a sale of common stock.
• The transaction involved the disposition of 3,719 shares of common stock on March 16, 2026.
• The shares were sold at a weighted average price of $5.1213 per share, with prices ranging from $5.11 to $5.1301.
• The sale was non-discretionary and executed automatically to satisfy tax withholding obligations arising from a restricted stock units award vesting and settlement event.
• Following this transaction, Ashwath Jayagopal directly beneficially owns 516,775 shares of Opus Genetics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary sale to cover tax obligations, not indicative of a change in the executive's or company's outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The shares were sold automatically on behalf of the Reporting Person to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award.
• This transaction does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a common and routine occurrence in the industry. Such transactions are typically non-discretionary and are generally not interpreted as an indication of management's sentiment regarding the company's future prospects or stock performance.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in company fundamentals or management's confidence.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale of shares by an executive to cover tax withholding obligations associated with restricted stock unit vesting. This is a routine event and does not provide new information that would alter the fundamental investment thesis for Opus Genetics. Therefore, a 'hold' recommendation is appropriate as there's no new catalyst for a change in position.

Keywords

Opus Genetics, IRD, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Ashwath Jayagopal